Literature DB >> 28432377

Emerging roles of calpain proteolytic systems in macrophage cholesterol handling.

Takuro Miyazaki1, Akira Miyazaki2.   

Abstract

Calpains are Ca2+-dependent intracellular proteases that play central roles in the post-translational processing of functional proteins. In mammals, calpain proteolytic systems comprise the endogenous inhibitor calpastatin as well as 15 homologues of the catalytic subunits and two homologues of the regulatory subunits. Recent pharmacological and gene targeting studies in experimental animal models have revealed the contribution of conventional calpains, which consist of the calpain-1 and -2 isozymes, to atherosclerotic diseases. During atherogenesis, conventional calpains facilitate the CD36-dependent uptake of oxidized low-density lipoprotein (LDL), and block cholesterol efflux through ATP-binding cassette transporters in lesional macrophages, allowing the expansion of lipid-enriched atherosclerotic plaques. In addition, calpain-6, an unconventional non-proteolytic calpain, in macrophages reportedly potentiates pinocytotic uptake of native LDL, and attenuates the efferocytic clearance of apoptotic and necrotic cell corpses from the lesions. Herein, we discuss the recent progress that has been made in our understanding of how calpain contributes to atherosclerosis, in particular focusing on macrophage cholesterol handling.

Entities:  

Keywords:  ATP-binding cassette transporters; Atherosclerosis; Cholesterol efflux; Efferocytosis; Low density lipoprotein; Pinocytosis; Scavenger receptor

Mesh:

Substances:

Year:  2017        PMID: 28432377     DOI: 10.1007/s00018-017-2528-7

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  99 in total

1.  Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Venkateswaran Subramanian; Haruhito A Uchida; Talha Ijaz; Jessica J Moorleghen; Deborah A Howatt; Anju Balakrishnan
Journal:  J Cardiovasc Pharmacol       Date:  2012-01       Impact factor: 3.105

Review 2.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

Authors:  D Steinberg; S Parthasarathy; T E Carew; J C Khoo; J L Witztum
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

3.  Spatial localization of m-calpain to the plasma membrane by phosphoinositide biphosphate binding during epidermal growth factor receptor-mediated activation.

Authors:  Hanshuang Shao; Jeff Chou; Catherine J Baty; Nancy A Burke; Simon C Watkins; Donna Beer Stolz; Alan Wells
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

Review 4.  High-density lipoprotein--the clinical implications of recent studies.

Authors:  D J Gordon; B M Rifkind
Journal:  N Engl J Med       Date:  1989-11-09       Impact factor: 91.245

Review 5.  Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies.

Authors:  Carlos Silvestre-Roig; Menno P de Winther; Christian Weber; Mat J Daemen; Esther Lutgens; Oliver Soehnlein
Journal:  Circ Res       Date:  2014-01-03       Impact factor: 17.367

6.  A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance.

Authors:  L J Baier; P A Permana; X Yang; R E Pratley; R L Hanson; G Q Shen; D Mott; W C Knowler; N J Cox; Y Horikawa; N Oda; G I Bell; C Bogardus
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

Review 7.  Phagocytosis in atherosclerosis: Molecular mechanisms and implications for plaque progression and stability.

Authors:  Dorien M Schrijvers; Guido R Y De Meyer; Arnold G Herman; Wim Martinet
Journal:  Cardiovasc Res       Date:  2006-09-16       Impact factor: 10.787

8.  Probucol inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and to its proteolytic degradation.

Authors:  Cheng-Ai Wu; Maki Tsujita; Michi Hayashi; Shinji Yokoyama
Journal:  J Biol Chem       Date:  2004-05-12       Impact factor: 5.157

9.  Epidermal growth factor activates m-calpain (calpain II), at least in part, by extracellular signal-regulated kinase-mediated phosphorylation.

Authors:  A Glading; R J Bodnar; I J Reynolds; H Shiraha; L Satish; D A Potter; H C Blair; A Wells
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

10.  Dissecting the roles of Rac1 activation and deactivation in macropinocytosis using microscopic photo-manipulation.

Authors:  Makoto Fujii; Katsuhisa Kawai; Youhei Egami; Nobukazu Araki
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more
  7 in total

1.  The SNP43 (G/A) polymorphism in CAPN10 gene confers an increased risk of cognitive impairment in cerebral small vessel disease.

Authors:  Kai Wu; Ying Cai
Journal:  J Clin Lab Anal       Date:  2018-07-16       Impact factor: 2.352

Review 2.  Effects of functionally diverse calpain system on immune cells.

Authors:  Yueqi Chen; Zhaoliang Su; Fang Liu
Journal:  Immunol Res       Date:  2021-01-23       Impact factor: 2.829

Review 3.  Dysregulation of Calpain Proteolytic Systems Underlies Degenerative Vascular Disorders.

Authors:  Takuro Miyazaki; Akira Miyazaki
Journal:  J Atheroscler Thromb       Date:  2017-08-17       Impact factor: 4.928

Review 4.  Defective Protein Catabolism in Atherosclerotic Vascular Inflammation.

Authors:  Takuro Miyazaki; Akira Miyazaki
Journal:  Front Cardiovasc Med       Date:  2017-12-07

Review 5.  Pinocytotic engulfment of lipoproteins by macrophages.

Authors:  Takuro Miyazaki
Journal:  Front Cardiovasc Med       Date:  2022-08-29

Review 6.  Calpain proteolytic systems counteract endothelial cell adaptation to inflammatory environments.

Authors:  Takuro Miyazaki; Risako Akasu; Akira Miyazaki
Journal:  Inflamm Regen       Date:  2020-04-02

Review 7.  CAPN6 in disease: An emerging therapeutic target (Review).

Authors:  Lin Chen; Dongqiong Xiao; Fajuan Tang; Hu Gao; Xihong Li
Journal:  Int J Mol Med       Date:  2020-09-21       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.